GHK-Cu vs GLOW Blend: Single Peptide or Blend?
GHK-Cu is a single copper peptide; the GLOW Blend is a 70 mg vial that holds 50 mg GHK-Cu plus 10 mg BPC-157 and 10 mg TB-500. The core difference is the question being asked: GHK-Cu alone isolates one copper peptide and its collagen and skin literature, while GLOW pairs that same 50 mg of GHK-Cu with two peptides studied for soft-tissue repair, at a fixed ratio. Here is what each component brings, what the research shows, and when a single vial makes more sense than the blend.
Findings
- GLOW’s GHK-Cu content is 50 mg, the same as the 50 mg GHK-Cu vial, so the blend adds BPC-157 and TB-500 on top rather than diluting the copper peptide.
- GHK-Cu stimulated collagen synthesis in fibroblasts from 10-12 to 10-11 M (1988), and topical GHK-Cu reached 98.5% median closure of diabetic foot ulcers against 60.8% for vehicle (1994).
- BPC-157 is a 15-amino-acid peptide from gastric juice; it accelerated tendon fibroblast outgrowth and migration in culture (2011), and a 2025 systematic review found improved outcomes in muscle, tendon, ligament and bone injury models.
- Thymosin beta-4 increased wound re-epithelialisation by 42% at day 4 and up to 61% at day 7 in rats (1999); analysis of TB-500 identified a seven-amino-acid fragment of it carrying the actin-binding motif (2012).
- No study of the GLOW blend as a single formulation was identified; the evidence covers each component.
What is in each vial?
| Component | GHK-Cu vial | GLOW Blend vial |
|---|---|---|
| GHK-Cu | 50 mg or 100 mg | 50 mg |
| BPC-157 | None | 10 mg |
| TB-500 | None | 10 mg |
| Total | 50 mg or 100 mg | 70 mg |
By mass, GHK-Cu makes up about 71% of a GLOW vial, at a 5 to 1 to 1 ratio. Both are blue in solution because of the copper, as explained in why GHK-Cu is blue. The blend’s makeup is set out in Buy GLOW Blend in Canada.
What does GHK-Cu research cover?
GHK (glycyl-histidyl-lysine) was described in 1973 as a tripeptide in human serum (Pickart and Thaler, Nat New Biol), and its plasma level falls from about 200 ng/mL at age 20 to 80 ng/mL by age 60 (Pickart and Margolina, Int J Mol Sci, 2018). Its copper complex stimulated collagen synthesis in fibroblast cultures, peaking at 10-9 M without changing cell number (Maquart et al., FEBS Lett, 1988). A 2015 review describes GHK raising collagen, dermatan sulphate, chondroitin sulphate and decorin, modulating metalloproteinases and their inhibitors, and drawing immune and endothelial cells to injuries (Pickart et al., Biomed Res Int, 2015).
In human research, a multicentre, randomised, evaluator-blinded, placebo-controlled trial in diabetic neuropathic ulcers found GHK-Cu gel tripled the rate of closure and cut infections to 7% against 34% for vehicle (Mulder et al., Wound Repair Regen, 1994); a 13-patient trial after laser resurfacing found higher satisfaction but no objective difference (Miller et al., Arch Facial Plast Surg, 2006). The full skin record is in GHK-Cu: The Skin Research.
What do BPC-157 and TB-500 add?
BPC-157
BPC-157 is a 15-amino-acid partial sequence of body protection compound, a protein isolated from human gastric juice. In rat Achilles tendon explants it significantly accelerated fibroblast outgrowth, improved cell survival under oxidative stress and increased fibroblast migration in a dose-dependent way, through the FAK-paxillin pathway (Chang et al., J Appl Physiol, 2011). A 2025 systematic review screened 544 records and included 36 studies, 35 of them preclinical; in those models BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries (Vasireddi et al., HSS J, 2025). The one clinical report, a retrospective chart review, found 14 of 16 patients reported knee-pain relief after injection of BPC-157 alone or with thymosin beta-4 (Lee and Padgett, Altern Ther Health Med, 2021). More is in BPC-157 Research and the Knee-Pain Data.
TB-500
TB-500 is built on thymosin beta-4, a 43-amino-acid peptide regarded as the main actin-sequestering molecule in mammalian cells. In a rat full-thickness wound model, thymosin beta-4 given topically or into the peritoneum increased re-epithelialisation by 42% over saline at day 4 and by up to 61% at day 7, with more collagen deposition and new blood vessels (Malinda et al., J Invest Dermatol, 1999). A seven-amino-acid actin-binding motif was shown to be essential for its angiogenic activity (Philp et al., FASEB J, 2003), and a doping-control analysis identified that region, the acetylated 17 to 23 fragment Ac-LKKTETQ, in a product sold as TB-500 (Esposito et al., Drug Test Anal, 2012). See TB-500 and Thymosin Beta-4: The Repair Research.
How do GHK-Cu and GLOW compare at a glance?
| Question | GHK-Cu | GLOW Blend |
|---|---|---|
| What is it? | Copper-bound tripeptide | GHK-Cu, BPC-157 and TB-500 in one vial |
| Size | 3 amino acids plus copper | Three peptides, including the 15-amino-acid BPC-157 |
| Main research area | Collagen, skin, wound closure | Skin plus soft-tissue repair |
| Mechanism focus | Fibroblast matrix synthesis | Matrix synthesis, cell migration, angiogenesis |
| Human evidence | Topical diabetic ulcer trial | Per component only; none for the blend |
| Ratio control | Full | Fixed at 5 to 1 to 1 |
| Forms we supply | 50 mg and 100 mg vials, nasal spray | 70 mg vial, nasal spray |
When does each one fit?
- Single-variable copper peptide work: GHK-Cu alone. Collagen synthesis, gene expression and skin models are cleaner to read without two other peptides in the vial.
- Higher GHK-Cu quantities: the 100 mg GHK-Cu vial carries twice the copper peptide of a GLOW vial.
- Designs that combine skin and soft-tissue questions: GLOW, which brings the collagen literature together with BPC-157’s tendon and ligament models and thymosin beta-4’s wound data in one reconstitution.
- Different ratios or separate timing: single vials of GHK-Cu, BPC-157 and TB-500, because a blend fixes the proportions.
If inflammation is also a variable, the KLOW Blend adds 10 mg KPV to the same three; see KLOW vs GLOW.
How are GHK-Cu and GLOW supplied?
GHK-Cu comes as 50 mg and 100 mg lyophilised vials and a ready-mixed GHK-Cu Nasal Spray; GLOW as a 70 mg vial and a ready-mixed GLOW Nasal Spray, metered at 0.175 mL per press. Vials are reconstituted with bacteriostatic water (see the GHK-Cu and GLOW reconstitution guides). Both are kept cold and dark after mixing, as covered in how long GHK-Cu lasts. Certificates of analysis are on the lab reports page, and every order ships from within Canada.
GHK-Cu and the GLOW Blend are supplied for laboratory research use only. The studies above used their own preparations of each individual peptide, not this blend.
Frequently asked questions
What is the difference between GHK-Cu and GLOW?
GHK-Cu is a single copper-bound tripeptide. GLOW is a 70 mg blend of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, which adds two soft-tissue repair peptides to the same amount of GHK-Cu found in a 50 mg vial.
How much GHK-Cu is in GLOW?
50 mg per 70 mg vial, about 71% of the blend by mass. That matches the 50 mg GHK-Cu vial; the 100 mg vial carries twice as much.
Is GLOW stronger than GHK-Cu?
Not in GHK-Cu content, which is the same 50 mg. GLOW adds BPC-157 and TB-500, which have their own research areas. No study has compared the blend with GHK-Cu alone.
Why is GLOW blue?
Because of the copper bound to GHK. Clear blue is normal for GHK-Cu, GLOW and KLOW; yellowing or a cloudy blue is not.
Where can I buy GHK-Cu and GLOW in Canada?
Vistara Labs supplies GHK-Cu as 50 mg and 100 mg vials and a nasal spray, and GLOW as a 70 mg vial and a nasal spray, shipped from within Canada by Canada Post Xpresspost.
Product details from vistaralabs.ca, October 2026. Sources: Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973. PMID 4349963. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018. PMID 29986520. Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMID 26236730. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PMID 17147644. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID 40756949. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435. Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PMID 10469335. Philp D et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003. PMID 14500546. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PMID 22962027.
More on this: Peptides for Skin: What the Research Shows.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
